No Data
No Data
No Data
No Data
No Data
Selling Apellis Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Even though Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) has fallen by 15% over the past week , insiders who sold US$7.9m worth of stock over the past year have had less luck. Given that the average s
Simply Wall StApr 18 08:41 ET
Wells Fargo Remains a Hold on Apellis Pharmaceuticals (APLS)
TipRanksApr 18 06:45 ET
Analysts Conflicted on These Healthcare Names: Enliven Therapeutics (ELVN), Alkermes (ALKS) and Apellis Pharmaceuticals (APLS)
TipRanksApr 18 01:10 ET
Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush
Apellis Pharmaceuticals Is Maintained at Neutral by Wedbush
Dow JonesApr 17 12:37 ET
Wedbush Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $57
Wedbush analyst Laura Chico maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Neutral and lowers the price target from $67 to $57.
BenzingaApr 17 12:26 ET
Express News | HC Wainwright & Co. Reiterates Buy on Apellis Pharmaceuticals, Maintains $92 Price Target
Moomoo 24/7Apr 15 07:07 ET
No Data
No Data